Methods
Introduction
Autotaxin (ATX), a secreted lysophospholipase, plays a central role in the production of the bioactive lipid lysophosphatidic acid (LPA). LPA signals through multiple LPA receptors to control a range of cell activities (migration, contraction, survival…). Recently, a role for the ATX/LPA axis in asthma and fibrosis were reported, suggesting involvement in additional lung diseases.
Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment values of 224 and 131 nM, respectively and a K i of 15 nM). Similar potency was observed ex vivo in the human and mouse LPA18:2 plasma assay. In the human ex vivo plasma assay, GLPG1690 reduced several LPA species with similar potency. In GLPG1690-treated mice, an inverse relationship was shown between LPA18:2 and GLPG1690 plasma levels reflecting in vivo target engagement. 
Conclusion
GLPG1690, a potent and selective ATX inhibitor, dose-dependently reduced LPA both ex vivo and in vivo. GLPG1690 displayed high efficacy in a preclinical model for COPD, with pronounced effect on the BALF cell count and lung gene expression profile, pointing to a novel therapeutic indication for autotaxin inhibitor. GLPG1690 has shown a favorable profile for development, efficacy in a preclinical model for IPF (1) with supportive clinical Phase 1 data (2) and is moving to a exploratory Phase 2a study in IPF.
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